ArticleChina CDC weekly2025
Progress and Challenges in the Global Elimination of Viral Hepatitis D.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis D virus (HDV) is a defective virus whose replication depends on hepatitis B virus (HBV) surface antigen (HBsAg). HBV/HDV coinfection represents the most severe form of viral hepatitis, substantially accelerating progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma. In response to the World Health Organization's (WHO) 2030 elimination target for viral hepatitis as a major public health threat, HDV elimination has emerged as one of the most formidable challenges, driven by its unique biological characteristics, widespread underdiagnosis, and historical absence of effective therapies. This article reviews key global advances in HDV epidemiology, screening and diagnosis, therapeutic development, and public health strategies. We provide an in-depth analysis of current barriers to elimination and offer strategic insights to guide future control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.